Tiagabine
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Tiagabine
|
|
| Systematic (IUPAC) name | |
| (3S)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl] piperidine-3-carboxylic acid | |
| Identifiers | |
| CAS number | |
| ATC code | N03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C20H25NO2S2 |
| Mol. mass | 375.55 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 90% |
| Protein binding | 96% |
| Metabolism | Hepatic (CYP450 system) |
| Half life | 7-9 hours |
| Excretion | Fecal and renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Tiagabine (pronounced /taɪˈæɡəbiːn]/[1]) is an anti-convulsive medication produced by Cephalon and marketed under the brand name Gabitril. The medication is also used in the treatment for panic disorder as are a few other anticonvulsants.
Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
[edit] Side effects
Tiagabine's most common side effects include confusion, difficulty speaking clearly/stuttering, mild sedation, and in doses over 8 mg, a tingling sensation (paresthesia) in the body's extremities, particularly the hands and fingers.
[edit] External links
- Gabitril (manufacturer's website)
 |
This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it. |
